Table 2. Summary of Base-Case Analyses.
| Factor | Pembrolizumab | Nivolumab | Incremental nivolumab vs pembrolizumab |
|---|---|---|---|
| LYs | 1.02 | 1.21 | 0.19 |
| QALYs | 0.75 | 0.89 | 0.14 |
| Drug acquisition cost, $ | 59 586 | 60 496 | 910 |
| Drug administration cost, $ | 845 | 1374 | 529 |
| Subsequent treatment cost, $ | 11 206 | 10 134 | −1071 |
| Follow-up cost, $ | 18 528 | 22 413 | 3885 |
| Best supportive care cost, $ | 23 732 | 33 440 | 9708 |
| Terminal care cost, $ | 10 539 | 10 488 | −51 |
| Adverse event cost, $ | 612 | 903 | 291 |
| Immunohistochemical test cost, $ | 107 | 107 | 0 |
| Overall cost, $ | 125 154 | 139 356 | 14 201 |
| Overall cost (discounted), $ | 121 257 | 133 073 | 11 816 |
| ICER, $/LY | NA | NA | 62 114 |
| ICER, $/QALY | NA | NA | 86 983 |
Abbreviations: ICER, incremental cost-effectiveness ratio; LYs, life-years; NA, not applicable; QALYs, quality-adjusted life-years.